Ignite Creation Date:
2024-05-05 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367237
Status:
COMPLETED
Last Update Posted:
2017-04-11
First Post:
2006-08-18
Brief Title:
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease RESPOND Study P04422
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Randomized Multicenter International Open-label Study of Infliximab Plus Methotrexate Versus Methotrexate MTX Alone for the Treatment of MTX naïve Subjects With Active Psoriatic Arthritis
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate IFX MTX versus methotrexate alone MTX in methotrexate naïve active psoriatic arthritis patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2005-002189-12 | None | None | None |